Modified ypTNM Staging Classification for Gastric Cancer after Neoadjuvant Therapy: A Multi-Institutional Study
Authors:
Open Access
- 17 September 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 26 (1) , e99-e110
Abstract
Background: The benefits of neoadjuvant therapy for patients with locally advanced gastric cancer (GC) are increasingly recognized. The 8th edition of the American Joint Committee on Cancer (AJCC) Staging Manual first proposed ypTNM staging, but its accuracy is controversial. This study aims to develop a modified ypTNM staging. Patients and Methods: Clinicopathological data of 1,791 patients who underwent curative-intent gastrectomy after neoadjuvant therapy in the Surveillance, Epidemiology, and End Results database, as the development cohort, were retrospectively analyzed. Modified ypTNM staging was established based on overall survival (OS). We compared the prognostic performance of the AJCC 8th edition ypTNM staging and the modified staging for patients after neoadjuvant therapy. Results: In the development cohort, the 5-year OS for AJCC stages I, II, and III was 58.8%, 39.1%, and 21.6%, respectively, compared with 69.9%, 54.4%, 34.4%, 24.1%, and 13.6% for modified ypTNM stages IA, IB, II, IIIA, and IIIB. The modified staging had better discriminatory ability (C-index: 0.620 vs. 0.589, p < .001), predictive homogeneity (likelihood ratio chi-square: 140.71 vs. 218.66, p < .001), predictive accuracy (mean difference in Bayesian information criterion: 64.94; net reclassification index: 35.54%; integrated discrimination improvement index: 0.032; all p < .001), and model stability (time-dependent receiver operating characteristics curves) over AJCC. Decision curve analysis showed that the modified staging achieved a better net benefit than AJCC. In external validation (n = 266), the modified ypTNM staging had superior prognostic predictive power (all p < .05). Conclusion: We have developed and validated a modified ypTNM staging through multicenter data that is superior to the AJCC 8th edition ypTNM staging, allowing more accurate assessment of the prognosis of patients with GC after neoadjuvant therapy. Implications for Practice: The 8th edition of the American Joint Committee on Cancer (AJCC) Staging Manual first proposed ypTNM staging, but its accuracy is controversial. Based on multi-institutional data, this study developed a modified ypTNM staging, which is superior to the AJCC 8th edition ypTNM staging, allowing more accurate assessment of the prognosis of patients with gastric cancer after neoadjuvant therapy.Keywords
Funding Information
- China Scholarship Council (201908350095)
- Construction Project of Fujian Province Minimally Invasive Medical Center (2017]171)
- National Natural Science Foundation of China (81802312)
- Scientific and technological innovation joint capital projects of Fujian Province (2017Y9011, 2017Y9004, 2018Y9041)
- Funded Project of Fujian Medical University Innovation and Entrepreneurship Training Program ((S202010392006))
This publication has 36 references indexed in Scilit:
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerNew England Journal of Medicine, 2012
- Is the New Seventh AJCC/UICC Staging System Appropriate for Patients with Gastric Cancer?Journal of the American College of Surgeons, 2012
- The Bayesian information criterion: background, derivation, and applicationsWIREs Computational Statistics, 2011
- Significance of Histopathological Tumor Regression After Neoadjuvant Chemotherapy in Gastric AdenocarcinomasAnnals of Surgery, 2011
- The Validity Of Cancer Specific Mortality Within The Surveillence, Epidemiology, And End Results RegistryJournal of Surgical Research, 2011
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- A Novel Subclassification of pT2 Gastric Cancers According to the Depth of Muscularis Propria InvasionAnnals of Surgery, 2009
- Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric JunctionJournal of Clinical Oncology, 2009
- Decision Curve Analysis: A Novel Method for Evaluating Prediction ModelsMedical Decision Making, 2006
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006